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Background 
 
 Research has demonstrated a relationship between cancer and the human 
immune system.  Certain cancers have a higher incidence in patients with compromised 
immune systems.  An example occurs in organ transplant patients who are taking 
immunosuppressive drugs and go on to develop post-transplant lymphoproliferative 
disease (PTLD).  PTLD complicates between 2% and 20% of solid organ transplants 
performed annually in the United States and is associated with the Epstein-Barr Virus 
(EBV) infection in 95% of the cases. 
 
Epstein-Barr Virus 
 EBV is the best known and most widely studied herpes virus and was also the 
first virus implicated in a human cancer.  EBV is associated with other cancers, such as 
Burkitt’s lymphoma, Hodgkin’s disease, and Kaposi’s sarcoma.  A unique feature of the 
virus is that it is present, although dormant, for the lifetime of 90% of immunocompetent 
adults.  EBV infection can arise during childhood and adolescence and occurs as 
infectious mononucleosis (“mono”) in 50% of these humans.  Healthy immune systems 
create T cells (immune cells in the blood) that are capable of controlling the EBV 
infection. T cells become specific for EBV by recognizing the peptide from EBV proteins 
on the surface of an antigen presenting cell (APC) (reference figure 1).  Healthy humans 
are able to activate CD8+ cytotoxic T lymphocytes (CTLs) to recognize and eliminate 
virus-infected cells.  However, humans with compromised immune systems are unable 
to produce sufficient T cells to control the infection [1]. 
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Post-Transplant Lymphoproliferative Disease 
 
 Post-Transplant Lymphoproliferative Disease (PTLD) is typically linked to EBV 
infection and has many features of immune system malignancy. Recently, the incidence 
of PTLD has been on the rise and it has emerged as a significant complication of solid 
organ and cell transplantation [2]. It is characterized by uncontrolled proliferation of B 
cells when post-transplant patients are undergoing immunosuppresion. PTLD presents 
significant challenges for physicians because it is difficult to predict and has high 
morbidity and mortality rates.  
 Patients undergoing organ transplants have compromised immune systems due 
to the immunosuppressive medications they are prescribed in order to avoid organ-
rejection. Because of this, these patients have impaired immune function and lack the 
capabilities to fight off EBV and other typically dormant viruses. Therefore, these 
patients become more likely than immunocompetent humans to develop PTLD.  
There are currently a variety of methods that physicians have been using to 
attempt to treat PTLD. Researchers and clinicians are in need of a treatment method 
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that is able to both treat the tumor and maintain an immunosuppressed state to 
preserve the organ donation [3, 4, 5]. This has been attempted through the reduction of 
immunosuppressive medications, radiotherapy, chemotherapy, cell therapy, antiviral 
therapy, and cytokine therapy.  
In a recent study, a reduced amount of immunosuppressive drugs was 
administered in order to reactivate the immune system to attack the EBV-associated 
tumor [6]. This did, in fact, reduce the tumor in 9 of 11 patients, but led to organ 
rejection in 5 cases.  This study, for the first time, showed an increase in the 
CD3+CD8+ T cells in patients that went into remission. Another recent study used HLA 
tetramers complexed with EBV immunodominant peptides and found that a subset of 
CD3+CD8+ T cells were EBV specific [1]. They also found in a severe combined 
immune deficient (SCID) mouse model system, as well as in patients, that the 
expansion of an EBV protein, BZLF1 (RAK) specific CD8+ T cells, correlated with the 
prevention of PTLD after a combined cytokine treatment. These findings opened a door 
in the research of human cellular subsets in mediating this protective effect.  
A vaccine approach to increase the quantity of T cells is a possible treatment 
method that could be beneficial to many patients.  Since PTLD results in mortality in 50-
70% of patients, a vaccine to reduce the frequency of infection could be especially 
advantageous to organ transplant patients. 
 
 
We hypothesized that a vaccine of BZLF1 protein transduced monocyte-derived 
antigen presenting cells (dendritic cells) will stimulate the expansion of Epstein-
Barr Virus (EBV) BZLF1-specific cytotoxic CD8+ T lymphocytes (CTLs).  
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In order to complete this, we developed two specific aims: 
 
Aim 1 – Goal A: Synthesize a BZLF1/GST fusion protein using the Glutathione S-
transferase (GST) gene fusion system from prokaryotic cells. 
    Goal B: Synthesize a BZLF1/ V5-His fusion protein from mammalian cells. 
Aim 2: Determine if monocyte-derived DCs pulsed with BZLF1 fusion proteins stimulate 
expansion of EBV BZLF1-specific CTLs.  
   
Methods 
 
 
Preparation of the Target Protein 
 
 The preparation and purification of BZLF1, an EBV viral protein, was 
accomplished using standard protocols provided by Novagen and Invitrogen 
Corporation for Goals A and B respectively (reference flow sheet 1). For Goal A, EBV 
BZLF1 cDNA was cloned into a prokaryotic expression vector, pET, obtained from 
Abgent Inc. 
 For Goal B, a mammalian expression vector, pUB6/V5-His, was prepared by 
digestion with restriction enzymes (EcoR1 and BamH1) and dephosphorylation with calf 
intestinal alkaline phosphatase. The vector was then gel purified. Next, the insert DNA 
containing a BZLF1 coding sequence was prepared. This was accomplished by plasmid 
prep and PCR (in order to amplify the BZLF1 coding sequence). This was followed by a 
restriction digest with (EcoR1 and BamH1) and gel purification.  The DNA insert was 
then ligated into the pUB6/V5-His vector.  
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 For both Goals A and B, each insert/vector pair was transformed into the DH5α 
strain of E. coli cells. These cells served as an expression host. Finally, the expression 
of BZLF1 was analyzed. A positive clone was sequenced and the expression of BZLF1 
protein was detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and a Western blot. The positive clones of generated stable Chinese 
Hamster Ovarian (CHO) cell lines were expanded in order to generate a large quantity 
and cell pellets were frozen at -80˚C until purification took place.  
 
 
Purification of the Target Protein 
 
 For Goal A, the BZLF1 was purified following a standard protocol (GST 
purification kit from Amersham Bioscience).  
 For goal B, the BZLF1 was purified following standard protocol provided by 
Invitrogen’s ProBond Purification System. The cell lysate was prepared under native 
conditions and added to a prepared His affinity column. The lysate was allowed to bind 
to the resin, then the column was washed, and the protein was eluted. The protein 
concentration was measured at UV280 and the eluted fractions were stored at 4˚C. 
Samples of the lysate and wash supernatants were also saved for SDS-PAGE analysis.  
 
Functional test of the Purified Target Protein 
 Next, functional testing of the purified BZLF1 protein was conducted (reference 
flow sheet 2). First, monocyte-derived dendritic cells transduced with BZLF1 protein 
were generated by culturing hPBMC for 3 days, with cytokine GM-CSF and IFN-α in the 
presence of EBV BZLF1 protein. BSA (Bovine Serum Proteins) served as a negative 
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control. The presence of the BZLF1 protein in the dendritic cells was determined by 
immunohistochemistry staining. Next, dendritic cells transduced with BZLF1 were co-
cultured with hPBMC from the same donor (autologous). Following the culture, BZLF1-
specific T cells were expanded. The activation and cytotoxicity of the generated BZLF1-
specific T cells was also determined. The activation of CD8+ T cells was determined by 
IFN-γ secretion assayed by an IFN-γ-Elispot or by intracellular IFN-γ staining. The 
cytotoxicity of CD8+ BZLF1-specific T cells was determined by co-cultured CD8+ T cells 
with a 51Cr-labeled B cell line derived from the same donor. The cytotoxicity of T cells 
was then calculated based on the percentage of 51Cr released. 
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Preparation and Purification of the Target Protein 
 
Flow Sheet 1 (Goal B specifically) 
 
  
Process 
 
Prepare pUB6/V5-His Vector 
↓ 
 
Prepare Insert DNA 
(BZLF-1 coding sequence) 
↓ 
Clone Insert into pUB6/V5-His Vector 
 
↓ 
 
 
 
 
Transform into Expression Host 
(E. coli) 
↓ 
 
Analysis of BZLF1 Expression 
And  
Generate CHO stable cell lines 
↓ 
 
Scale-up 
↓ 
Purify Target Protein 
 
 
Detail 
 
1. Digest with restriction enzyme 
and dephosphorylate 
2. Gel purify 
 
1. Plasmid prep and PCR 
2. Restriction digest  
3. Gel purify 
 
1. Ligate or anneal insert with 
pUB6/V5-His vector 
2. Transform into non-expression 
host 
3. Identify positive clones; colony 
PCR, prepare plasmid DNA, 
verify reading frame by 
sequencing, or in vitro 
transcription/translation 
 
 
 
 
1. Transform DH5α E. coli cells 
 
 
 
 
1. Detect target protein by SDS-
PAGE, Western blot 
 
 
 
 
 
1. Scale up culture 
2. Prepare extract 
3. His Affinity column purification 
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Test of the Purified Target Protein 
 
Flow Sheet 2
 
 
             Process 
 
Generation of monocyte-derived DCs 
transduced with BZLF1 protein 
 
↓ 
 
Expansion of BZLF1 specific T cells  
↓ 
 
Determination of activation and 
cytotoxicity of generated BZLF1 specific 
T cells             
            
 
 
 
 
 
 
 
 
 
Detail 
 
1. Culture hPBMC short term (5 
days) with GM-CSF in the 
presence of EBV BZLF1 protein. 
2.  The presence of BZLF1 protein in 
 DCs will be determined by an 
 immunohistochemistry staining.  
3. Co-culture BZLF1+ DCs with 
hPBMC from same donor 
 
4. The activation of CD8+ T cells       
can be determined by IFN 
gamma secretion assayed by a 
gamma IFN-Elispot.  
 
5. The cytotoxicity of CD8+ BZLF1 
specific T cells will be determined 
by co-cultured CD8+ T cells with 
a 51Cr labeled same donor 
derived B cell line. The 
cytotoxicity of the T cells will be 
calculated based on the 
percentage of 51Cr released. 
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Results 
 
 The intention of Aim 1-Goal B was to synthesize EBV BZLF1-GST fusion protein 
in vitro.  In order to generate a BZLF1 protein fused with the GST tag, EBV BZLF1 full 
length cDNA was amplified by Polymerase Chain Reaction (PCR) and cloned into a 
vector (pET vector, figure 1). The pET vector was prepared by digestion with restriction 
enzymes (BamHI and HindIII) and dephosphorylation with calf intestinal alkaline 
phosphatase. The vector was then gel purified. The cloning was successful as 
evidenced by many more colonies produced from ligation in the presence of the insert 
compared with the negative control. The positive clones were identified by colony PCR 
and restriction enzyme digestion. 
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 The BZLF1 was then expressed in appropriate competent cells (BL21).  At this 
point, the expression of the BZLF1 protein was optimized by analyzing plasmid stability 
and protein solubility. The BZLF1 protein expression was induced with IPTG, detected, 
and purified. The purity of the isolated EBV BZLF1 protein was determined by a 
Western blot using a monoclonal antibody against BZLF1 (figure 2). The Western blot 
shows that the IPTG induced BZLF1 protein expression, as shown in figure 2, lanes 6 
and 8 compared with lane 1. 
 
A pET vector was prepared and BZLF1 cDNA was inserted. 
MCS 
BamH1 Hind III 
BZLF1 cDNA 
Figure 1 
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Western Blot of IPTG Induction 
 
 
 
To test the efficacy of in vitro synthesized and purified EBV BZLF1 protein, 
human monocyte-derived DCs were generated after a 3 day culture in the presence of 
GM-CSF, IFN-α, and purified GST-BZLF1 protein. DCs that were treated in the same 
way, but cultured in the presence of BSA instead of GST-BZLF1, served as the control 
group.  The BZLF1-loaded DCs were then co-cultured with human peripheral blood 
1      2      3     4     5     6    7      8 
Lane 1: No IPTG 
Lane 2: IPTG without purification 
Lane 3: Lysate before sonication 
Lane 4: Insoluble pellet 
Lane 5: N/A  
Lane 6: 10/50 ul IPTG 
Lane 7: N/A 
Lane 8: 20/50 ul IPTG 
 
Figure 2 
IPTG induced BZLF1 protein expansion (lanes 6 & 8). 
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leukocytes (hu-PBL) with the matched HLA type for two weeks.  On day 14, the 
expansion and activation of BZLF1-specific CD8+ T cells was determined by flow 
cytometry (figure 3).   
 
BZLF1-GST promotes RAK CD8+ specific T cell expansion 
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After cloning and purification, the function of this process was analyzed. The 
expansion of CD8+ CTLs was determined by flow cytometry. A tetramer system was 
used to detect antigen-specific CD8+ CTL expansion (RAK tetramer), while FLR 
tetramer was used as a negative control.  
Top (red): cultured in the presence of BSA  
Bottom (pink): cultured in the presence of GST-BZLF1 
Figure 3 
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 The intention of Aim 1-Goal B was to synthesize EBV BZLF1-V5-His fusion 
protein in vitro from mammalian cells. In order to generate a BZLF1 protein fused with 
the V5-His tag, EBV BZLF1 was amplified by PCR and cloned into a vector (pUB6/V5-
His vector, figure 4). The pUB6/V5-His vector was prepared by digestion with restriction 
enzymes (BamHI and EcoR I) and dephosphorylation with calf intestinal alkaline 
phosphatase. The vector was then gel purified. The cloning was successful as 
evidenced by many more colonies produced from ligation in the presence of the insert 
compared with the negative control.  The positive clones were identified by colony PCR 
and restriction digestion. 
 
 
 
Figure 4 
BZLF1 protein fused with the V5-His tag was cloned 
into a pUB6/V5-His vector (above). 
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 Meanwhile, stable Chinese Hamster Ovarian (CHO) cell lines were generated. 
The culture was scaled up, the extract was prepared, and the cells were harvested by 
trypsinization.  The BZLF1 protein was purified following standard protocol provided by 
Invitrogen’s ProBond Purification System. The cell lysate was prepared under native 
conditions and added to a prepared His affinity column. The lysate was allowed to bind 
to the resin before the column was washed and the protein eluted. The protein 
concentration was measured at UV280 and the eluted fractions were analyzed by SDS-
PAGE (Figure 5) and Western blot using a monoclonal antibody against BZLF1 (Figure 
6). 
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{ {{A                    B                      C
1          2           3           4          5          6      7          8          9          10
Lane 1: protein standard                                       Lane 8:  C lysate (2.5ul, total lysate: 8ml) 
Lane 2: + ctrl, BZLF1 protein (no tag)                 Lane 9:  C #1 fraction (30ul/1ml in total)
Lane 3: A lysate (2.5ul, total lysate: 8ml)             Lane 10: C #2 fraction (30ul/1ml in total)
Lane 4: A #1 fraction (30ul/1ml in total)         
Lane 5: A #2 fraction (30ul/1ml in total)        A: lysates from CHO/BZLF1 stable cells
Lane 6: B lysate (2.5ul, total lysate: 8ml)       B: lysates from CHO-S cells transfected w/ BZLF1 T72 hrs
Lane 7: B #2 fraction (30ul/1ml total)            C: lysates from CHO cells transfected w/ BZLF1 T72 hrs
1st antibody: anti-BZLF1 at 1:1000
2nd antibody: Goat anti-mouse 1:2500
 
Figure 5 
SDS-PAGE analysis of BZLF1 
A very faint band corresponding to 33-kd is seen. In addition, 
bands corresponding to co-purified cellular proteins are 
present. 
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Lane 1: protein standard                                       Lane 8:  C lysate (2.5ul, total lysate: 8ml) 
Lane 2: + ctrl, BZLF1 protein (no tag)                 Lane 9:  C #1 fraction (30ul/1ml in total)
Lane 3: A lysate (2.5ul, total lysate: 8ml)             Lane 10: C #2 fraction (30ul/1ml in total)
Lane 4: A #1 fraction (30ul/1ml in total)         
Lane 5: A #2 fraction (30ul/1ml in total)        A: lysates from CHO/BZLF1 stable cells
Lane 6: B lysate (2.5ul, total lysate: 8ml)       B: lysates from CHO-S cells transfected w/ BZLF1 T72 hrs
Lane 7: B #2 fraction (30ul/1ml total)            C: lysates from CHO cells transfected w/ BZLF1 T72 hrs
1st antibody: anti-BZLF1 at 1:1000
2nd antibody: Goat anti-mouse 1:2500
1          2           3           4          5          6      7          8          9          10
{ {{A                    B                      C
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 
Western Blot analysis of BZLF1 
The Western Blot shows a specific band corresponding 
to 33-kd (lanes 8, 9, 10) similar to the band 
corresponding to the positive control (lane 2). 
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Discussion 
 
 For most healthy individuals, EBV infections are not life threatening and are 
generally effectively controlled by the immune system through the action of specific T 
lymphocytes [7, 8]. EBV-specific T lymphocytes recognize peptides from EBV proteins 
which are expressed on the surface of EBV- infected or EBV-transformed B 
lymphocytes [8]. Both CD8+ CTL and CD4+ helper T lymphocytes (HTL) can 
discriminate EBV-infected /transformed B cells and, therefore, are able to inhibit their 
growth [7]. Although most normal individuals are immune to EBV for their entire lives, 
the virus is not completely eliminated, but instead persists in a latent infection state [9, 
10, 11], which is effectively controlled by the EBV-specific T lymphocytes [8]. However, 
in immunosuppressed individuals such as organ transplant patients, primary EBV 
infection usually results in Post-Transplant Lymphoproliferative Disease (PTLD), which 
often progresses into B cell lymphomas [12, 13, 14]. 
 Unfortunately, current therapeutic approaches for PTLD and lymphomas are far 
from optimal. The reduction of immunosuppressive therapy allows for the immune-
mediated viral elimination, but consequently, there is a high risk of organ rejection in 
these patients. In addition, the effectiveness of antiviral agents is not clear at this time 
[14]. One of the most effective ways to prevent/treat PTLD and B cell lymphomas is via 
adoptive immunotherapy using EBV-specific T lymphocytes [15, 16]. Unfortunately, this 
approach is labor intensive, costly, and not widely available [7]. The risk of PTLD and 
lymphoma increases significantly in patients who lacked immunity to EBV before 
transplantation and who are undergoing immunosuppressive therapy [17]. It is possible 
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that this risk could be lowered if EBV-seronegative patients could be immunized to 
stimulate their T lymphocytes, but unfortunately such a vaccine is not yet available [7]. 
 PTLD is a devastating post transplantation complication and [18] as organ 
transplants continue to increase in number, and the risk of organ rejection decreases 
because of the improvements in immune suppressive therapy, PTLD will continue to be 
a significant problem [1]. Since physicians lack a reliable treatment of PTLD, it is 
important to develop a successful way of treating these patients as soon as possible.  
 An appealing and practical approach to develop vaccines that are intended to 
elicit antigen-specific T cell responses is the use of synthetic peptides representing CTL 
and HTL epitopes [7]. This strategy has been explored for various viral and malignant 
diseases [19, 20, 21, 22]. A large number of T cell epitopes derived from EBV latent and 
lytic cycle antigens have been identified, and many of these are being considered as 
potential vaccine candidates [23, 24]. Many of these efforts are focusing on using 
histocompatibility antigen (HLA) class I-restricted peptide epitopes to induce CD8+ CTL 
responses to EBV, since these cells are considered to be the prime effector cells that 
will presumably destroy the virus-infected and transformed cells [7]. There is also recent 
evidence that CD4+ T lymphocytes can function as potent effectors for inhibiting EBV-
induced B cell proliferation, which would be the initial step of PTLD [25].  
 An important possible drawback of T cell peptide epitope vaccines is the 
limitation of HLA restriction. Most CTL and HTL peptide epitopes will only be useful in 
the limited proportion of individuals who express the appropriate HLA allele. However, in 
the case of HLA class II epitopes, some peptides have been found to bind 
indiscriminately to more than one HLA allele [26, 27, 28]. In some cases, these 
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indiscriminate epitopes can bind up to 10 common HLA alleles, indicating that the 
majority of the population would recognize these epitopes [29]. Therefore, a large 
proportion of patients would be able to benefit from a vaccine in which the peptide is 
able to bind to multiple HLA alleles. 
 We hypothesized that a vaccine of BZLF1 full protein transduced monocyte-
derived dendritic cells (DCs) would stimulate the expansion of EBV BZLF1-specific 
cytotoxic CD8+ T lymphocytes (CTLs) efficiently. We demonstrated that this did, in fact, 
occur. When T-cell expansion was analyzed by flow cytometry, we determined that 
BZLF1-GST promoted RAK CD8+ specific T-cell expansion, while the BSA did not.  
 In order to determine the efficiency of this approach in humans, an in vivo study 
of the vaccine using severe combined immune deficient (SCID) mice will be done. In 
order for the T-cell expansion to occur effectively, the conditions under which the BZLF1 
protein is purified must first be optimized, however. The SCID mice lack functional T 
and B lymphocytes. This lack of an effective immune response coupled with the intact 
hematopoietic microenvironment allows the SCID mouse to be reconstituted with 
human bone marrow or peripheral blood lymphocytes [30]. Giving these mice human 
blood from individual donors who are EBV positive gives rise to human B-cell tumors in 
the mice. We hypothesize that giving these mice the BZLF1 protein will increase RAK 
CD8+ T-cell expansion and prevent PTLD in these animals.  
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